CDK4 and cancer: For instance, treatment with CDK4/6 inhibitors (e.g., palbociclib) may induce dephosphorylation and/or downregulation of RB1 in specific cancer types [34, 35], which is accompanied by decreased NUDT15 expression in various cell lines according to the public databases (e.g., GSE74620, GSE133568, and GSE177054) (Figure 3J).